Entries by admin

ARCADIA BIOSCIENCES RECEIVES U.S. PATENT FOR EXTENDED SHELF LIFE TOMATOES

Technology Helps Vine-Ripened Tomatoes Stay Fresh from Farm to Table DAVIS, Calif. (July 17, 2014) — Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, today announced that the U.S. Patent and Trademark Office has granted the company a key technology patent for Extended […]

Neos Therapeutics Announces Positive Phase 3 Study Results for its Methylphenidate Extended-Release (XR) Oral Disintegrating Tablet (ODT) in ADHD Patients

Grand Prairie, TX (July 15, 2014) –  CMEA Capital portfolio company Neos Therapeutics, Inc. (“Neos” or “the Company”), a highly differentiated oral drug delivery company with a portfolio of proprietary technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced today that it has completed a positive Phase 3 study for […]

Baxano Surgical Announces First Clinical Use of the Avance MIS Pedicle Screw System

Raleigh, NC – June 30, 2014 (GLOBE NEWSWIRE) —  CMEA Capital portfolio company Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that the first case utilizing the AvanceT MIS Pedicle Screw System was recently performed by […]

Ardelyx Announces Pricing Of Its Initial Public Offering

FREMONT, Calif., June 18, 2014  — CMEA Capital portfolio company Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced the pricing of its initial public offering of 4,286,000 shares of common stock at a public offering price of $14.00 per share. The shares are expected to begin trading on […]

ARCADIA BIOSCIENCES LAUNCHES SONOVA® ULTRA GLA SAFFLOWER OIL

Next-Generation Dietary Supplement Offers the Highest Concentration of Oilseed GLA Available DAVIS, Calif. (June 17, 2014) – CMEA Captial portfolio company Arcadia Biosciences, Inc., an agricultural biotechnology company focused on developing technologies and products that benefit the environment and enhance human health, announced the commercial launch of SONOVA® ULTRA GLA Safflower Oil. With 55 percent gamma linolenic […]

Neos Therapeutics, Inc. Announces the Appointment of Richard I. Eisenstadt as Chief Financial Officer

Dallas/Fort Worth, TX  (May  22, 2014) – CMEA Capital portfolio company Neos Therapeutics, Inc. (“Neos” or “the Company”), a highly differentiated oral drug delivery company with an exciting portfolio of proprietary technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced today the appointment of Richard I. Eisenstadt to the role of Chief Financial […]

Ardelyx Receives $25 Million Milestone From AstraZeneca For Commencement Of Phase 2b Clinical Trial Of Tenapanor

Study will evaluate tenapanor for the treatment of hyperphosphatemia in ESRD patients on hemodialysis   FREMONT, Calif., May 15, 2014 /PRNewswire/ — Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced that it has received a $25 million milestone payment from AstraZeneca (NYSE:AZN, LON:AZN) for the initiation of a […]

ARCADIA BIOSCIENCES RAISES $33 MILLION SERIES D INVESTMENT

DAVIS, Calif. (May 8, 2014) – CMEA Capital portfolio company Arcadia Biosciences, Inc., an agricultural biotechnology company focused on developing technologies and products that benefit the environment and human health, announced today that it has closed on a $33 million round of Series D preferred share equity financing. The round was led with an investment […]

‘Adderall’ up: Neos gets $18M series C plus $20M loan deal for AD

Neos Therapeutics Inc.’s upsized series C financing – from $15.5 million to $18 million – along with a $20 million loan facility with Hercules Technology Growth Capital Inc. means the firm will “not only have enough money to hit the key regulatory milestones over the next 12-15 months, but to give us financial flexibility into […]